Biotia Funding: How Much Did They Raise & Key Investors

How Much Did Biotia Raise?
Funding & Key Investors

Biotia has successfully secured a significant capital injection, bringing its total funding to $10.6M. This latest major strategic investment of $8M underscores the market confidence in the company's proprietary genomic and artificial intelligence platform. By leveraging advanced sequencing technology, Biotia continues to solidify its position as a critical player in the global infectious disease diagnostics landscape, moving from its early-stage roots toward a more mature enterprise-level operational phase.

The company's growth trajectory, marked by a series of strategic financing rounds, reflects a robust commitment to scaling its diagnostic capabilities. With this recent infusion of capital, Biotia is well-positioned to accelerate its research and development initiatives, further enhancing its ability to provide rapid, accurate identification of microorganisms for clinical and research applications.

What is Biotia?

Biotia

Business Services

Research & Development

Healthcare Services

Biotia operates at the intersection of genomics and artificial intelligence, providing sophisticated diagnostic solutions for infectious diseases. The company's product suite, including the BIOTIA-DX and BIOTIA-ID lines, serves a diverse clientele ranging from clinical practitioners to academic researchers. By integrating high-throughput sequencing with proprietary AI algorithms, Biotia enables the precise detection of pathogens, which is essential for managing complex infections in urinary and joint health. Their strategic collaborations with high-profile institutions like the Mayo Clinic and the Rockefeller Foundation validate their technological approach and underscore their role in modernizing global health monitoring systems.

How much funding has Biotia raised?

Biotia has raised a total of $10.6M across 3 funding rounds:

2019

Angel/Seed

$2.4M

2021

Debt

$155K

2022

Series A

$8M

Angel/Seed (2019): $2.4M with participation from Falcon III Ventures and Hyperplane Venture Capital

Debt (2021): $155K led by PPP

Series A (2022): $8M, investors not publicly disclosed

Key Investors in Biotia

Hyperplane Venture Capital

A Boston-based seed stage firm that partners with founders leveraging machine intelligence and cloud computing to solve complex problems at the nexus of perception and insight.

Falcon III Ventures

An investment firm focused on identifying and supporting high-growth potential companies within the technology and healthcare innovation sectors.

PPP

Public-Private Partnership

What's next for Biotia?

With the recent influx of capital, Biotia is poised to expand its clinical footprint and refine its diagnostic pipeline. The company is expected to focus on scaling its commercial operations and deepening its integration within hospital systems, where rapid pathogen identification is paramount for patient outcomes. Future strategic efforts will likely center on broadening the scope of their AI-driven insights to address emerging infectious disease threats, thereby reinforcing their competitive advantage in the biotech sector. As they transition into this next phase of growth, the focus will remain on operational excellence and the continued validation of their genomic sequencing technologies in real-world clinical environments.

See full Biotia company page

See More Financial Insights